Brief: Prelude Therapeutics Inc Anticipates Existing Cash Will Fund Operations Into Q4 Of 2024
08/05/2023 13:17
May 8 (Reuters) - Prelude Therapeutics Inc PRLD.O :
* PRELUDE THERAPEUTICS INC - ANTICIPATES THAT EXISTING
CASH, CASH
EQUIVALENTS AND MARKETABLE SECURITIES WILL FUND OPERATIONS INTO
THE Q4 OF 2024
* PRELUDE THERAPEUTICS INC - QTRLY LOSS PER SHARE $0.58
Source: (https://shorturl.at/ntzB9)
Further company coverage: PRLD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Prelude Therapeutics Incorporated
See all newsBrief: Prelude Announces Clinical Trial Collaboration And Supply Agreement With Lilly To Evaluate KAT6A Selective Degrader PRT13722 In Combination With Verzenio® And Inluriyo® In Patients With HR+/HER2- Breast Cancer
U.S. RESEARCH ROUNDUP-Celcuity, Fluence Energy, Salesforce
Prelude Therapeutics Incorporated reports results for the quarter ended June 30 - Earnings Summary
Prelude Therapeutics Q2 revenue beats analyst expectations, net loss narrows
Prelude Therapeutics Incorporated expected to post a loss of 20 cents a share - Earnings Preview